Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy
J Charles Henry1, James H Peace2, Jeanette A Stewart3,4, William C Stewart3,41Little Rock Eye Clinic, Little Rock, AR, USA; 2Diabetic Eye Medical Clinic, Inglewood, CA, USA; 3PRN Pharmaceutical Research Network, LLC, Dallas,TX, USA; 4Carolina Eye Institute, University of South Carolina, School of Me...
Main Authors: | J Charles Henry, James H Peace, Jeanette A Stewart, William C Stewart |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2008-10-01
|
Series: | Clinical Ophthalmology |
Online Access: | http://www.dovepress.com/efficacy-safety-and-improved-tolerability-of-travoprost-bak-free-ophth-a2369 |
Similar Items
-
Efficacy, safety, and tolerability of travoprost 0.004% BAK-free versus prior treatment with latanoprost 0.005% in Japanese patients
by: Michael J Miyashiro, et al.
Published: (2010-11-01) -
Efficacy and patient tolerability of travoprost BAK-free solution in patients with open-angle glaucoma and ocular hypertension
by: Sophia K Mirza, et al.
Published: (2010-07-01) -
A comfort comparison of travoprost BAK-free 0.004% versus latanoprost 0.005% in patients with primary open-angle glaucoma or ocular hypertension
by: David A Godfrey, et al.
Published: (2009-01-01) -
First experience with BAK-free travoprost 0.004% in topical glaucoma medication
by: Gado AS, et al.
Published: (2011-12-01) -
Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost
by: Gregory Katz, et al.
Published: (2010-11-01)